FDG PET in a Patient on a GLP-1 Agonist/Insulin Secretagogue.
Clin Nucl Med
; 49(9): e436-e438, 2024 Sep 01.
Article
em En
| MEDLINE
| ID: mdl-38914020
ABSTRACT
ABSTRACT With the increase in use of GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy, Rybelsus) in the population, nuclear medicine physicians should be aware of the possibility of nondiagnostic FDG PET scans due to these medications, which work partly by increasing insulin secretion. We demonstrate a case where a patient's use of such a medication presumptively led to muscular and myocardial uptake, complicating scan interpretation considerably. Clinicians should be aware of the presence of these drugs and their potential effect on biodistribution in FDG PET. Further study is needed to best understand the effects of these medications on FDG biodistribution.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Fluordesoxiglucose F18
/
Tomografia por Emissão de Pósitrons
Limite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Clin Nucl Med
Ano de publicação:
2024
Tipo de documento:
Article